



RLL-244US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: SALMAN et al.

U.S. Serial No.: 10/511,399

Filing Date: November 8, 2004

Title: AZOLE DERIVATIVES AS ANTIFUNGAL AGENTS

CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation w/references
- Return Postcard


is being deposited on May 27, 2005 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Dolci
Susan Dolci

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.

RLL-244US

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,399	11/08/2004	TBA	26815	TBA	6687

Title: AZOLE DERIVATIVES AS ANTIFUNGAL AGENTS

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR


the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
RLL-244US

In Re Application: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,399	11/08/2004	TBA	26815	TBA	6687



AZOLE DERIVATIVES AS ANTIFUNGAL AGENTS

MAY 31 2005

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
 - Charge the amount of _____.
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

5-27-05

(Date)

Signature

Signature of Person Mailing Correspondence

Signature

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: May 27, 2005

William D. Hare
Reg. No. 44,739
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel.: (609) 720-5334
Fax: (609) 514-9779

CC:


INFORMATION DISCLOSURE CITATION

Docket No.: RLL-244US Serial No.: 10/511,399

Applicants: SALMAN *et al.*

Filed: 10/14/2004

Group:



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,034,248	3/7/2000	Itoh <i>et al.</i>	548	253	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
	B1	JP 2000-63364	2/29/2000	Japan	C07D	249/08	<input type="checkbox"/>
							<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Fromtling, "Overview of Medically Important Antifungal Azole Derivatives", <i>Clinical Microbiology Reviews</i> , 1(2):187-217 (1988)
C2	Greenspan, "Treatment of oropharyngeal candidiasis in HIV-positive patients", <i>The Journal of the American Academy of Dermatology</i> , 31:S51-S55 (1994)
C3	Georgopapadakou and Walsh, "Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies", <i>Antimicrobial Agents and Chemotherapy</i> , 40(2):279-291 (1996)
C4	Georgopapadakou, "Antifungals targeted to the cell wall", <i>Expert Opinion on Investigational Drugs</i> , 6(2):147-150 (1997)
C5	Kauffman and Carver, "Antifungal Agents in the 1990s", <i>Drugs</i> , 53(4):539-549 (1997)
C6	Koltin and Hitchcock, "The search for new triazole antifungal agents", <i>Current Opinions in Chemical Biology</i> , 1:176-182 (1997)
C7	<u>Antifungal Agents</u> , "Principles and practice of infectious diseases", 4 th ed. pgs 401-410, G.L. Mandel, J.E. Bennett and R.Dolin (ed.), Churchill Livingstone, Inc. New York, N.Y
C8	Nguyen <i>et al.</i> , "The Changing Face of Candidemia: Emergence of Non-Candida albicans Species and Antifungal Resistance", <i>The American Journal of Medicine</i> , 100(6):617-623 (1996)
C9	Sheehan <i>et al.</i> , "Current and Emerging Azole Antifungal Agents", <i>Clinical Microbiology Reviews</i> , 12(1):40-79 (1999)
C10	Perfect <i>et al.</i> , "In Vitro and In Vivo Efficacies of the Azole SCH56592 against <i>Cryptococcus neoformans</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , 40(8):1910-1913 (1996)
C11	36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1996, New Orleans

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-244US	Serial No.: 10/511,399
	Applicants: SALMAN <i>et al.</i>	
	Filed: 10/14/2004	Group:

C12	Naito <i>et al.</i> , "ER-34346 Triazole Antifungal", <i>Drugs of the Future</i> , <u>21</u> (1):20-24 (1996)
C13	<i>Chem. Pharm. Bull.</i> , <u>48</u> :12, 1947 (2000)
C14	Database CAS Online on STN, chem. Abstr., Accession No. 2000:401815, WO 2000034267 (Takeda Chemical Industries, Ltd.) 15 June 2000, abstract

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	